FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic Rare Disease in Nephrology
17 juin 2024 08h30 HE
|
NovelMed Therapeutics Inc
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase II, Efficacy Trial in adult AAV patients has...
$43+ Billion Cell and Gene Therapy Clinical Trials Market Forecast, 2024-2034, by Therapy Type, Phase, Indication, and Region
05 juin 2024 03h41 HE
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Clinical Trials Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's...
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03 avr. 2024 07h00 HE
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
02 avr. 2024 07h26 HE
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...
Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight Report 2024: Combining CDC7 Kinase Inhibitors with Existing Cancer Therapies for Enhanced Efficacy
11 janv. 2024 05h28 HE
|
Research and Markets
Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
08 janv. 2024 08h30 HE
|
NovelMed Therapeutics Inc
The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone in the drug development process.Ruxoprubart is an...
Over 15 ATR Protein Inhibitors in Clinical Trials, Signifying Significant Advancements in Cancer Pharmaceutical Research
09 nov. 2023 06h43 HE
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. A...
World Edema Clinical Trials (Phase I, Phase II, Phase III, Phase IV) Market Size, Share & Trends Analysis Report 2023-2030
06 nov. 2023 06h23 HE
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Participant (Pediatrics,...
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
30 oct. 2023 08h00 HE
|
NovelMed Therapeutics Inc
The Phase I healthy trial revealed that NM8074 effectively blocked the alternative pathway (AP) and AP-mediated C3b deposition without affecting the classical pathway (CP). Importantly, NM8074 did not...
Navigating Trials in Crisis: A Comprehensive Look at Global COVID-19 and Long COVID Clinical Trials Amidst Disruptions
01 sept. 2023 11h33 HE
|
Research and Markets
Dublin, Sept. 01, 2023 (GLOBE NEWSWIRE) -- The "Clinical Trials - Impact of COVID-19 and Long COVID" report has been added to ResearchAndMarkets.com's offering.This report provides an overview of...